Industry | Pharmaceutical |
---|---|
Founded | 2000 |
Headquarters | Parsippany, NJ |
Area served | Worldwide |
Products | Broad-spectrum antibiotics |
Website |
melinta |
Melinta Therapeutics, founded in 2000 as Rib-X Pharmaceuticals, is an American publicly traded biopharmaceutical firm that focuses on the design and development of novel broad-spectrum antibiotics for the treatment of antibiotic-resistant infections in hospital settings. The company is located in Parsippany, New Jersey. [1]
In mid-2011, Sanofi entered into a global research collaboration and licensing option with the company to develop and commercialize novel antibiotics. [2] It was renamed Melinta Therapeutics in 2013. [3]
One of its products, delafloxacin (Baxdela), a fluoroquinolone antibiotic acquired from Wakunaga Pharmaceutical in 2006, [2] was approved by the FDA in 2017. [4]
As of 2016, the company was also developing radezolid, a next-generation oxazolidinone for bacterial acne. [3]
Melinta shredded off its discovery research team in late 2018. [5] It also moved its headquarters from New Haven to Morristown, New Jersey in early 2019.
On December 27, 2019, Melinta Therapeutics filed for Chapter 11 bankruptcy protection. [6]
In April 2020, it was transferred to affiliates of its creditor Deerfield Management. [5]
{{
cite news}}
: CS1 maint: DOI inactive as of January 2024 (
link)